- Home
- PRQR vs MRCC Comparison
PRQR vs MRCC Comparison
Compare PRQR & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRQR | MRCC |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.3M | 135.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PRQR | MRCC |
|---|---|---|
| Price | $1.45 | $6.18 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | $7.67 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 408.8K | 98.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.71% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.07 | $5.86 |
| 52 Week High | $3.10 | $8.85 |
Technical Indicators
Market Signals| Indicator | PRQR | MRCC |
|---|---|---|
| Relative Strength Index (RSI) | 35.51 | 40.19 |
| Support Level | $1.33 | $5.96 |
| Resistance Level | $1.54 | $6.40 |
| Average True Range (ATR) | 0.09 | 0.18 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 31.94 | 28.17 |
Price Performance
Historical ComparisonAbout PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.